The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials

Author： Varkaris Andreas Corn Paul G Gaur Sanchaika Dayyani Farshid Logothetis Christopher J Gallick Gary E

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.12, 2011-12, pp. : 1677-1684

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HGF/c-MET Targeted Therapeutics: Novel Strategies for Cancer Medicine

Current Drug Targets, Vol. 12, Iss. 14, 2011-12 ,pp. : 2045-2058

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials

Clinical Cancer Drugs, Vol. 3, Iss. 2, 2016-10 ,pp. : 87-99

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials

Clinical Cancer Drugs, Vol. 3, Iss. 2, 2016-10 ,pp. : 87-99

Bentham Science Publishers

Access to resources Recommend Favorite

Development of c-MET pathway inhibitors

By Liu Xiangdong Newton Robert C Scherle Peggy A

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 9, 2011-09 ,pp. : 1225-1241

Informa Healthcare

Access to resources Recommend Favorite

The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer

Current Pharmaceutical Design, Vol. 18, Iss. 37, 2012-12 ,pp. : 6155-6168

Bentham Science Publishers

Access to resources Recommend Favorite